Senesco begins SNS01-T drug trial
The open-label, multiple-dose, dose-escalation study will also assess the impact of SNS01-T on time to relapse or progression and tumor response using multiple metrics. Senesco president and CEO
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.